1M alpha glycerylphosphorylcholine [choline-L-alfoscerate] 1 gJday was found to be
significantly more effective than 1M cytosine diphosphocholine 19Jday (which has been …

A multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the
efficacy and tolerability of L-α-glycerylphosphorylcholine (L-α-GPC) 1 gm/day IM compared …

The efficacy of cytidine diphosphate choline (CDP-choline) on chronic cerebrovascular
disease was evaluated in a multicentre, double-blind, placebo-controlled clinical trial …

A multicenter, unblinded, randomized, controlled clinical trial was conducted to evaluate the
efficacy and tolerability of L-aglycerylphosphorylcholine (La-GPC) 1 gm/day IM compared …

Cholinergic precursors have represented the first approach to counter cognitive impairment
occurring in adultonset dementia disorders. These compounds were early leaved because …

This paper has reviewed the documentation on the clinical efficacy of choline alphoscerate,
a cholinergic precursor, considered as a centrally acting parasympathomimetic drug in …

The neuroprotective glial cell modulator propentofylline has been used in clinical trials
involving more than 800 patients with vascular dementia (VaD). These data derive from two …

The clinical efficacy and the tolerability of alpha-glycerophosphocholine (alpha-GPC), a
drug able to provide high levels of choline for the nervous cells of the brain and to protect …

Damage to the brain from vascular disease is, after Alzheimer's disease, the second most
common cause of the dementia syndrome. Longitudinal studies have demonstrated that …

Ninety-two patients affected by chronic cerebrovasculopathy were treated with cytidine
diphosphate choline (CDP-choline) 1000 mg/day im or with placebo, in a double-blind …